XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.56 and traded as high as $2.79. XTL Biopharmaceuticals shares last traded at $2.6650, with a volume of 5,791 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Down 8.2%

The stock’s 50-day simple moving average is $2.56 and its 200 day simple moving average is $3.73. The company has a market cap of $5.19 million, a price-to-earnings ratio of -3.69 and a beta of 1.48.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.